Nucleated Cell Microvesicles for Targeted Drug Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current drug delivery systems, such as liposomes and red blood cell-derived vesicles, lack the ability to specifically target and deliver therapeutic or diagnostic substances to cancer cells or tissues, leading to adverse effects on normal cells and inefficient treatment outcomes.

Innovation Solution

Microvesicles derived from nucleated mammalian cells, which can be transformed to target specific cells or tissues, are used to deliver therapeutic or diagnostic substances, constructed using methods like extrusion, sonication, or electroporation, allowing for selective and effective delivery.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of stationary object

If liposomes are used as drug delivery systems, then the circulatory half-life is extended through PEG coating, but the ability to specifically target cancer cells is lost

Engineering Contradiction:

Improvecirculatory half-lifeVSAvoidtargeting ability

Core Design Contradiction:

Duration of action of stationary objectVSReliability

Solution Approach 1:

The patent combines the PEG coating technology from liposomes with cell membrane technology to create PEGylated cell membrane vesicles. This merging preserves the long circulatory half-life benefit of PEG while incorporating the targeting ability of cell membranes through surface proteins and ligands.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The invention creates a composite structure consisting of a cell membrane vesicle core coated with PEG polymers. This composite material integrates the biocompatibility and targeting capability of natural cell membranes with the extended circulation time provided by PEGylation, resolving the contradiction between durability and functionality.

Inventive Principle:

Principle #40Composite materials

2Stability of the object's composition

If red blood cell membranes are used for vesicle construction, then the circulatory stability is improved due to 120-day lifespan, but the targeting capability is lost because red blood cells are anucleated

Engineering Contradiction:

Improvecirculatory stabilityVSAvoidtargeting capability

Core Design Contradiction:

Stability of the object's compositionVSReliability

Solution Approach 1:

Instead of using anucleated red blood cells for stability, the patent inverts the approach by using nucleated mammalian cells that can be transformed. These cells provide both the stability needed for drug delivery and the genetic capability to express targeting ligands, eliminating the fundamental limitation of red blood cells.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The patent changes the source cell parameter from anucleated to nucleated, enabling genetic transformation while maintaining circulatory stability. By selecting appropriate mammalian cells and optimizing their properties, the system achieves both long circulation time and targeting capability through surface protein expression.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If monoclonal antibodies are added to liposomes for targeting, then the specific binding ability is improved, but the device complexity increases and clinical success is not achieved

Engineering Contradiction:

Improvespecific binding abilityVSAvoidsystem complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts the targeting function from the liposome structure itself and transfers it to cell membrane-derived vesicles that naturally possess surface proteins and ligands for specific binding. This eliminates the need for additional monoclonal antibody conjugation, reducing system complexity while maintaining targeting ability.

Inventive Principle:

Principle #2Taking out (Extraction)

4Reliability

If anticancer agents are delivered systemically, then the therapeutic effect is achieved, but the cytotoxicity to normal cells causes adverse effects

Engineering Contradiction:

Improvetherapeutic effectVSAvoidcytotoxicity to normal cells

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by equipping vesicles with specific targeting ligands that recognize and bind to receptors on cancer cell surfaces. This enables the therapeutic agent to be delivered preferentially to the target site, concentrating the effect locally while minimizing exposure and cytotoxicity to normal cells throughout the body.

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS10675244B2Microvesicles derived from nucleated, mammalian cells and use thereof

Publication Date: 2020.06.09 MDIMUNE INC

AI summary

The present invention relates to a microvesicle that is derived from nucleated mammalian cells, which are smaller than the nucleated cells. The microvesicles of the present invention can be used in the delivery of a therapeutic or diagnostic substance to specific tissues or cells, and more particularly, relates to microvesicles derived from monocytes, macrophages, dendritic cells, stem cells or the like, which can be used to deliver specific therapeutic or diagnostic substances for treating and/or diagnosing tissue associated with cancer, diseased blood vessels, inflammation, or the like.